A systematic review on the role of MSC-derived exosomal miRNAs in the treatment of heart failure

Background This systematic review summarizes results of studies that evaluated the expression of microRNAs (miRs) in pre-diabetes or type 2 diabetes. Methods The information was obtained in PubMed, EMBL-EBI, Wanfang, Trip Database, Lilacs, CINAHL and Google. A qualitative synthesis of the results was performed and miRs frequency was graphically. From 1880 we identified studies, only 53 fulfilled the inclusion criteria. The 53 studies analyzed miRs in T2D; and of them, thirteen also described data in pre-diabetes. Results In diabetics, 122 miRs were reported and 35 miRs for pre-diabetics. However, we identified that 5 miRs (-122-5p, 144-3p, 210, 375, -126b) were reported more often in diabetics, and 4 (144-3p, -192, 29a and -30d) in pre-diabetics. Conclusions Circulating miRs could be used as biomarkers of type 2 diabetes. However, it is necessary to validate these microRNAs in prospective and multi-center studies, where different population subgroups, considering the age, gender, and risk factors.

Automated summary

This systematic review summarizes studies on microRNA expression in pre-diabetes or type 2 diabetes. Several microRNAs were found to be more frequently reported in diabetics, such as miR-122-5p, 144-3p, 210, 375, and miR-126b, while miR-144-3p, -192, 29a, and -30d were more commonly reported in pre-diabetes. Circulating microRNAs could potentially be used as biomarkers for type 2 diabetes, but further validation in prospective and multi-center studies is needed.